【摘要】：目的探討二肽基肽酶4(DPP-4)抑制劑西格列汀對基質細胞衍生因子1α(SDF-1α)降解及胰島β細胞再生的影響。方法將高脂-小劑量STZ糖尿病模型大鼠分為糖尿病模型組與西格列汀組,正常大鼠為健康對照(NC)組,給藥12周后測量FPG、FIns、胰腺DPP-4、SDF-1α、胰島β細胞增殖、細胞骨髓瘤(C-myc)mRNA和細胞周期蛋白D1(CyclinD1)mRNA。結果治療后與NC組比較,糖尿病模型組FPG[(5.0±0.4)vs(26.8±3.6)mmol/L]、DPP-4[(14.63±2.19)vs(17.51±2.11)]、SDF-Iα[(2.84±1.97)vs(6.23±1.85)]升高,FIns[(24.9±7.4)vs(9.1±3.2)mU/L]降低(P0.05);與糖尿病模型組比較,西格列汀組FPG[(26.8±3.6)vs(10.8±5.4)mmol/L]、DPP-4[(17.51±2.11)vs(9.33±2.21)]降低,FIns[(9.1±3.2)講(16.7±6.5)mU/L]、SDF-1α[(6.23±1.85)vs(11.38±2.02)]增高(P0.05);NC組增殖細胞核抗原(PCNA)弱表達,糖尿病模型組PCNA弱陽性表達,西格列汀組PCNA強陽性表達;與NC組比較,糖尿病模型組和西格列汀組C-myc mRNA[(I.0±0.2)講(1.5±0.6)vs(3.7±1.1)]和CyclinD1 mRNA[(1.0±0.3)vs(1.7±0.5)vs(4.0±0.7)]均升高(P0.05)。結論DPP-4抑制劑西格列汀可抑制DPP-4酶活性而阻滯SDF-1α降解,提高WNT信號通路靶基因C-myc與Cyclin D1 mRNA表達,促使胰島β細胞增殖再生。
[Abstract]:Objective to investigate the effects of siglitatin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, on the degradation of stromal cell derived factor-1 偽 (SDF-1 偽) and islet 尾 cell regeneration. Methods High fat-low dose STZ diabetic rats were divided into diabetic model group and siglitatin group. Normal rats were used as healthy control (NC) group. After 12 weeks of administration, FPG,FIns, pancreatic DPP-4,SDF-1 偽, islet 尾 cell proliferation, cell myeloma (C-myc) mRNA and cyclin D1 (CyclinD1) mRNA. were measured. 緇撴灉娌葷枟鍚庝笌NC緇勬瘮杈，

本文編號：2203657